Sterile pharmaceutical manufacturing plant
Sri Lanka-based company Navesta Pharmaceuticals has opened a sterile manufacturing facility in the town of Horana in August 2017.
Construction began in October 2015, and the plant is said to be the first of its kind in Sri Lanka. The facility is intended to produce sterile dry powder injectables of beta lactam antibiotics, which were previously imported to the country.
Built with an investment of more than LKR1.4bn ($9.1m), the Horana facility has generated more than 100 direct and 500 indirect jobs for locals in areas including bio-chemistry, pharmaceutical sciences, molecular bio-science, drugs, engineering, and ancillary services.
The factory will allow Navesta to export its pharmaceutical products to markets globally, contributing to the country’s economic development. It will also support the Government of Sri Lanka’s aim to achieve self-sufficiency in the pharmaceutical industry by 2020.
Located in the Kalutara district, Navesta’s new factory has a total floor area of 40,000ft².
The plant is designed to comply with good manufacturing practice (GMP) standards set by the EU and the Pharmaceutical Inspection Cooperation Scheme (PIC/S).
An advanced building management system (BMS) at the facility ensures compliance with the EU-GMP and PIC/S standards. It is used to control humidity, temperature, and differential pressure at production and testing rooms to destroy all viable microorganisms.
The interior of the factory features cleanroom panels built with pre-coated galvanised iron to provide protection from external contaminants.
The facility is also fitted with environmentally sustainable features including energy efficient lighting and comprehensive waste water treatment systems.
The sterile pharmaceutical manufacturing factory is installed with 13 incubator chambers and two walk-in incubators, which are designed in compliance with 21 Code of Federal Regulations (CFR).
The plant also incorporates a Grade A and Grade B microbiology laboratory, which helps develop comprehensive advanced in-house testing methods.
The testing and measuring equipment installed in the facility are calibrated as per accreditation standard ISO 17025 and ISO 9001 to achieve valid results.
Navesta’s Horana sterile pharmaceutical manufacturing facility will initially produce 50 million vials a year for filling sterile dry powder injectables of Beta Lactam.
Pharmaceutical products to be produced at the factory will primarily serve the requirement of 12 penicillin-based beta-lactam antibiotics in the form of dry powder for the local market. They will also be exported to global markets, which accept EU-GMP and PIC/S accreditations.
The plant is planned to be expanded in future to further increase Navesta’s production capacity by three times in the coming years. If undertaken, the expension will provide approximately $500m of savings to the country, which currently imports $800m-worth pharmaceutical products a year.
Headquartered in Rajagiriya, Navesta Pharmaceuticals is engaged in manufacturing beta lactam antibiotics.
The company’s products include Ticarcillin-clavulanic, Piperacillin-tazobactam, Co-amoxiclav, Flucloxacillin, Cloxacillin, Ampicillin, Benzathine penicillin, Fortified Procaine Penicillin, and Benzylpenicillin.
Fujifilm Diosynth Biotechnologies (FDB), a subsidiary of Japanese conglomerate Fujifilm, is building a new cell culture manufacturing facility in Holly…
Regis Technologies, a US-based contract development and manufacturing organisation (CDMO), completed the expansion of its custom active pharmaceutical ingredients (APIs)…
US-based global pharmaceutical company Bristol-Myers Squibb (BMS) is building a new cell therapy manufacturing facility in Devens, Massachusetts, US. The…
UK-based biopharmaceuticals company Lakes BioScience is planning to build a pharmaceutical manufacturing plant in Ulverston, Cumbria, UK. The facility will…